Teriparatide
- CAS Codes:52232-67-4
- PHARMGKB ID:52232-67-4
Table of contents
- Brand Names
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Genes that may be involved
- Nutrition/Nutraceutical Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
Europe
Austria: Forsteo; Belgium: Forsteo; Bulgaria: Forsteo; Cyprus: Forsteo; Czech Republic: Forsteo; Denmark: Forsteo; Estonia: Forsteo; Finland: Forsteo; France: Forsteo; Germany: Forsteo; Greece: Forsteo; Hungary: Forsteo; Ireland: Forsteo; Italy: Forsteo; Latvia: Forsteo; Lithuania: Forsteo; Luxembourg: Forsteo; Malta: Forsteo; Netherlands: Forsteo; Poland: Forsteo; Portugal: Forsteo; Romania: Forsteo; Slovakia: Forsteo; Slovenia: Forsteo; Spain: Forsteo; Sweden: Forsteo; UK: Forsteo.
North America
Canada: Forteo; USA: Forteo.
Latin America
Argentina: Forteo; Brazil: Fortéo; Mexico: Forteo.
Asia
Japan: Human PTH, Teriparatide.
Drug combinations
Chemistry
Teriparatide: C~181~H~291~N~55~O~51~S~2~. Mw: 4117.72. (1) L-Phenylalanine, L-seryl-L-valyl-L-seryl-L-α-glutamyl-L-isoleucyl-L-glutaminyl-L-leucyl-L-methionyl-L-histidyl-L-asparaginyl-L-leucylglycyl-L-lysyl-L-histidyl-L-leucyl-L-asparaginyl-L-seryl-L-methionyl-L-α-glutamyl-L-arginyl-L-valyl-L-α-glutamyl-L-triptophyl-L-leucyl-L-arginyl-L-lysyl-L-lysyl-L-leucyl-L-glutaminyl-L-α-aspartyl-L-valyl-L-histidyl-L-asparaginyl-; (2) L-Seryl-L-valyl-L-seryl-L-α-glutamyl-L-isoleucyl-L-glutaminyl-L-leucyl-L-methionyl-L-histidyl-L-asparaginyl-L-leucylglycyl-L-lysyl-L-histidyl-L-leucyl-L-asparaginyl-L-seryl-L-methionyl-L-α-glutamyl-L-arginyl-L-valyl-L-α-glutamyl-L-tryptophyl-L-leucyl-L-arginyl-L-lysyl-L-lysyl-L-leucyl-L-glutaminyl-L-α-aspartyl-L-valyl-L-histidyl-L-asparaginyl-L-phenylalanine. CAS-52232-67-4 (1996).
Pharmacologic Category
Hormones and Synthetic Substitutes; Parathyroid.
Mechanism of action
A recombinant formulation of endogenous parathyroid hormone (PTH). Pharmacologic activity of teriparatide similar to physiologic activity of PTH, stimulating osteoblast function, increasing gastrointestinal calcium absorption, increasing renal tubular reabsorption of calcium. Treatment with teriparatide increases bone mineral density, bone mass, and strength. In postmenopausal women, it has been shown to decrease osteoporosis-related fractures.
Therapeutic use
Treatment of osteoporosis in postmenopausal women at high risk of fracture. Treatment of primary or hypogonadal osteoporosis in men at high risk of fracture.
Pregnancy and lactiation implications
Not indicated for use in pregnant or premenopausal women. Not recommended in nursing women (excretion in breast milk unknown).
Unlabeled use
Contraindications
Hypersensitivity to teriparatide or any component of the formulation.
Warnings and precautions
Teriparatide may cause orthostatic hypotension (use with caution in cerebrovascular disease, cardiovascular disease, hypovolemia, or concurrent medication use which may predispose to hypotension/bradycardia). Transient orthostatic hypotension usually occurs within 4 hours of dosing and within first several doses. Avoid use in increased risk of osteosarcoma (including Paget’s disease, prior radiation, unexplained elevation of alkaline phosphatase, or in open epiphyses). Do not use in history of skeletal metastases, hyperparathyroidism, or pre-existing hypercalcemia. Not for use in metabolic bone disease other than osteoporosis. Use with caution in cardiovascular disease, in hepatic and renal impairment, and in active or recent urolithiasis. Use of teriparatide for longer than 2 years not recommended.